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OBJECTIVES: As payers decision makers increasingly become primary gate-
keepers for access to novel therapies, pharmaceutical, biotech and medical 
device manufacturers strive to fulfill the evidentiary requests of the pharmacy 
benefit managers and plan medical directors. This study attempts to gather 
information to inform manufacturers on the need and rationale behind the 
payers’ requests of head-to-head controlled studies. METHODS: We interviewed 
11 medical directors (MD) and 2 pharmacy directors (PD) of commercial health 
insurance plans; 4 pharmacy benefit managers (PBM); and 2 MD of Medicaid 
programs. The interviews focused on understanding product coverage decision 
making and formulary placement. The interviewers followed a discussion guide, 
but encouraged deeper conversation when appropriate. The interviews were 
carried out in the summer of 2012 and beginning of 2013. RESULTS: Seven out of 
13 (54%) medical directors spontaneously mentioned the need for direct 
comparison data in clinical trials to ensure adequate decision making. 
Conversely, only one PD out of the PBMs and PDs even mentioned comparison 
data and that was in the context of trying to understand the clinical trial design. 
Two MDs went on to further to state that if the head-to-head data showed 
increased efficacy that a price premium would be appropriate. Another MD 
stated that the head-to-head data may assist in formulary placement decisions. 
CONCLUSIONS: Payers will continue to demand head-to-head studies as long as 
these studies are seen as the mechanism to address their questions. By fostering 
a richer dialogue with payers to explore other mechanisms for gathering the 
comparative data, manufacturers may be able to satisfy the payers’ needs with 
less risky and more relevant study designs.  
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OBJECTIVES: Industrialized countries are increasingly adopting pay-for-
performance (P4P) mechanisms for quality improvement. The purpose of this 
work is to present a decision program that is able to estimate the cost-
effectiveness, budget impact, and health benefits of P4P programs. METHODS: 
The decision program builds upon previously published decision models on the 
cost-effectiveness of implementation programs. The model analyzes the three 
possible benchmarks for rewarding performance - absolute performance, 
improved performance, and relative performance. RESULTS: The model shows 
that when P4P programs do not lead to a substitution of other health care 
programs their incremental cost-effectiveness ratio (ICER) is deterministically 
determined and ranges from treatment ICER to infinity. This holds regardless of 
the reward mechanism. In case of a budget constraint a P4P program will be 
adopted only if it substitutes other programs with lower financial incentive to 
providers. Budget impact and health benefits are calculated as the difference in 
costs and health benefits between the P4P program and the programs that are 
replaced. A P4P program is cost saving when the programs to be substituted have 
higher per patient costs despite a lower financial incentive. CONCLUSIONS: The 
proposed decision program is able to deterministically model the cost-
effectiveness and budget impact of P4P programs under different reward 
mechanism and in the presence or absence of a budget constraint.  
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Patient financial contributions or copayments are an important funding source 
for access to medicine in both developed and emerging markets. In the former, 
they are on the rise as fiscally strapped health systems shift costs to patients; in 
the latter, they are declining as governments expand public funding for access. 
In this paper, we address three topics. First, we characterize the systems of 
patient contributions in eleven established markets and eight emerging markets 
using data from IMS and international organizations such as OECD. We also 
quantify the current level of use and the trends in application of patient 
contributions. Second, we conduct a systematic review of research literature on 
the impact of patient contributions published between 2000 and 2012 to examine 
if they achieve their intended policy objectives in practice. Specifically, we look 
at the implications of patient contributions on whether they (1) encourage 
responsible or rational medicine use by patients; (2) allow governments to 
contain public health care costs while still sustaining patient access to 
treatments; (3) provide flexible choice for patients who want to pay for non-
essential or premium treatments; and (4) increase overall patient access to 
medicine by increasing funding for health care allowing public investment to 
focus on higher need patients, or if they tend to displace public investments 
thereby increasing inequity of health care provision. We find that in some cases, 
patient contributions have the desired effects, while in other cases they have 
limited or even opposite effects. Whether or not patient contributions achieved 
desired objectives depends on the design of the policy, e.g., if these contributions 
discriminated between treatment choices or not. Third, based on our findings, 
we draw out key elements that patient contribution systems must have to 
achieve their objectives in developed and emerging markets.  
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In many countries policy makers are concerned about an increase in drug 
expenditures. One particular concern is the group of patented drugs. The 
purpose of this work is to present a proportional rule for setting ceiling prices of 
new innovative drugs. In essence, a proportional rule sets out that drug prices 
should only increase in proportion to incremental effectiveness. The rule of 
proportionality has its theoretical foundation in economic consumer theory, 
which states that willingness to pay (for drugs) is a direct measure of the 
marginal value (of beneficiaries) and thus changes proportional to marginal 
value. By measuring health benefits on a cardinal value scale it is ensured that 
prices change in proportion to the size of health benefits, in accordance with 
economic consumer theory. The suggested proportional rule combines four 
desirable features: first, it contains the growth of health expenditures without 
the need to eliminate currently funded programs; second, it enables a rapid 
assessment of cost-effectiveness without the need to calculate downstream 
costs; third, its calculation method is transparent and easy to understand which 
helps pharmaceutical companies in making better predictions about whether 
their investment in R&D is worth it; and forth, it obviates the need to put an 
explicit dollar value on a person’s life. Optionally, the decision rule can account 
for additional aspects beyond an increase in health benefits: i) lack of growth of 
gross domestic product; ii) price difference between patented drugs and generic 
drugs; and iii) savings which go beyond the reduction in clinical events.  
In summary, the suggested proportional rule avoids many of the shortcomings  
of existing cost-per-QALY rules while limiting the introduction of new 
weaknesses.  
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Among the many definitions of economics are several that focus on the role that 
prices and income play in determining human behavior. In many 
pharmacoeconomic studies little attention is paid to different levels of prices 
and the resulting differences in behavior. More important, in most studies based 
on randomized controlled trials there is no variation in price to examine and 
variations in income are not even measured. It is not so much that the authors 
believe that prices and incomes have no effect on behavior. It is more that the 
effect is believed to be minor or the goal of the study is not really an economic 
one. This paper will review the impact of changing prices and income on the 
behavior of patients, providers, payers, and pharmaceutical companies. The 
discussion of patient behavior will focus on the value of patient time and the role 
of out-of-pocket costs in determining adherence. Physician and hospital 
behavior will be considered in light of market prices of their inputs and outputs. 
Government and private payer behavior will be characterized. A brief discussion 
of pharmaceutical company profit incentives will be included. Finally, we will 
review the information typically used to get on a formulary in the United States. 
We propose adding discussion of behavioral responses to changing market 
conditions in pharmacoeconomic submissions to regulatory bodies including 
those making formulary decisions.  
 
PHP154  
DISPOSAL OF DATE EXPIRED AND UNUSED MEDICINES IN INDIA– A 
CONCEPTUAL FRAMEWORK  
Udupa N1, Muragundi PM2, Naik AN2, Janodia M3 
1Manipal College of Pharmaceutical Sciences, Manipal, India, 2Manipal College of Pharmaceutical 
Sciences, Manipal, Karnataka, India, 3Manipal College of Pharmaceutical Sciences, Manipal 
University, Manipal, India  
The medicines used for common ailments are stored by many household  
for emergency use. Many times these medicines expire despite being stored 
under prescribed conditions. It is important to dispose these medicines that are 
date expired and unused in an appropriate manner. The guidelines for disposal 
for medicines are prescribed by World Health Organization (WHO) and United 
States Food and Drugs Administration (USFDA). Some of the methods suggested 
to dispose date expired and unused medicines include returning to 
manufacturer, landfill, and waste immobilization: encapsulation/ inertization, 
flushing it down the Sewer and incineration. Despite precautions associated  
with these methods, these methods are not effective. Studies have shown that 
these methods sometime poses a risk not only to human beings by increasing 
chances of taking wrong medications, accidental poisoning, adverse drug 
reactions, drug-drug interactions that increases health burden but also to  
the environment. In India, the knowledge regarding disposal of date expired  
and unused medicines is lacking among common people. A conceptual 
framework to dispose date expired and unused medicine is devised. Pharmacies 
interested in program would be identified wherein patients visiting  
these pharmacies would be asked to register with pharmacy and return  
the unused/date expired medicines to participating pharmacies. The unused  
and date expired medicines collected in pharmacies shall be segregated into 
various types by participating volunteers. The segregation would include various 
dosage forms and packing material. The recovered contents will be sent to a 
specialist company that uses specific procedures in order to recycle the collect 
reusable components and safely dispose of chemical components based on 
prescribed procedures. The reusable components shall be collected and property 
treated for reuse. This concept would not only sensitize people but also 
community pharmacists and would be advantageous to protection of 
environment.  
 
